Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.44 |
| ▸ | JAK1 | P23458 | 4/20 | 0.44 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 9/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | HTR1E | P28566 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211442 | 0.89 | HTR1D (0.46) | JAK2JAK1CDK7CDK9HTR1D | |
| SCHEMBL3217516 | 0.89 | JAK3 (0.46) | JAK2JAK1CDK7CDK9HTR1D | |
| SCHEMBL3220493 | 0.87 | CDK7 (0.42) | JAK2JAK1CDK7CDK9FLT3 | |
| SCHEMBL3217678 | 0.87 | CDK7 (0.45) | JAK2JAK1CDK7CDK9HTR1D | |
| SCHEMBL3214861 | 0.81 | JAK3 (0.39) | JAK2JAK1CDK7CDK9HTR1D | |
| SCHEMBL3661903 | 0.77 | HTR1D (0.44) | JAK1CDK7CDK9HTR1DFLT3 | |
| SCHEMBL3225505 | 0.77 | JAK2 (0.46) | JAK2JAK1CDK7CDK9HTR1D | |
| SCHEMBL3622286 | 0.77 | FLT3 (0.35) | JAK2JAK1CDK7CDK9HTR1D | |
| SCHEMBL3221635 | 0.76 | JAK2 (0.45) | JAK2JAK1CDK7CDK9HTR1D | |
| SCHEMBL7951141 | 0.76 | HTR1D (0.41) | JAK2JAK1CDK7CDK9HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056491-A1 | 4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR4, HTR3B | JAK2 1004/4885JAK1 3321/4885CDK7 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.